Minocycline: A review of its antibacterial and pharmacokinetic properties and therapeutic use - PubMed (original) (raw)

Minocycline: A review of its antibacterial and pharmacokinetic properties and therapeutic use

R N Brogden et al. Drugs. 1975.

Abstract

Minocycline is a semi-synthetic tetracycline derivative which is well absorbed and distributed in body tissues and is suitable for twice daily administration. It appears to be as generally effective as other tetracyclines and analogues, but also to be effective in infections due to tetracycline-resistant staphylococci. Side-effects are typical of those of other tetracyclines, but minocycline has been associated with a high incidence of vertigo in some studies. On the other hand, minocycline appears to have little or no photosensitising potential. It is not yet clear whether minocycline can be safely used in patients with moderate or severe impairment of renal function, but if used in renal failure, the plasma urea concentration should be monitored.

PubMed Disclaimer

Similar articles

• The glycylcyclines: a comparative review with the tetracyclines.
  Zhanel GG, Homenuik K, Nichol K, Noreddin A, Vercaigne L, Embil J, Gin A, Karlowsky JA, Hoban DJ. Zhanel GG, et al. Drugs. 2004;64(1):63-88. doi: 10.2165/00003495-200464010-00005. Drugs. 2004. PMID: 14723559 Review.
• Minocycline administered intravenously: pharmacological activity and clinical experience.
  Clark BJ, Hodgson CR, Dornbush AC, Hutchinson J. Clark BJ, et al. Curr Ther Res Clin Exp. 1974 Sep;16(9):865-77. Curr Ther Res Clin Exp. 1974. PMID: 4214661 Clinical Trial. No abstract available.
• [The treatment with minocyciline (Minocin) in daily pediatric practice (author's transl)].
  Rentsch M. Rentsch M. Schweiz Rundsch Med Prax. 1980 Nov 25;69(47):1756-9. Schweiz Rundsch Med Prax. 1980. PMID: 7255332 Clinical Trial. German. No abstract available.
• Clinical evaluation of intravenous minocycline.
  Rogers JH, Barnwell PA, Waterman NG, Austin FD, Raff MJ. Rogers JH, et al. Int J Clin Pharmacol Biopharm. 1977 Apr;15(4):194-8. Int J Clin Pharmacol Biopharm. 1977. PMID: 858651

Cited by

• Is the Neuroimmune System a Therapeutic Target for Opioid Use Disorder? A Systematic Review.
  Toloff K, Woodcock EA. Toloff K, et al. Med Res Arch. 2022 Aug;10(8):2955. doi: 10.18103/mra.v10i8.2955. Med Res Arch. 2022. PMID: 37744743 Free PMC article.
• Neurodegeneration, Mitochondria, and Antibiotics.
  Suárez-Rivero JM, López-Pérez J, Muela-Zarzuela I, Pastor-Maldonado C, Cilleros-Holgado P, Gómez-Fernández D, Álvarez-Córdoba M, Munuera-Cabeza M, Talaverón-Rey M, Povea-Cabello S, Suárez-Carrillo A, Piñero-Pérez R, Reche-López D, Romero-Domínguez JM, Sánchez-Alcázar JA. Suárez-Rivero JM, et al. Metabolites. 2023 Mar 12;13(3):416. doi: 10.3390/metabo13030416. Metabolites. 2023. PMID: 36984858 Free PMC article. Review.
• Reduced blood-brain barrier penetration of acne vulgaris antibiotic sarecycline compared to minocycline corresponds with lower lipophilicity.
  Grada A, Del Rosso JQ, Moore AY, Stein Gold L, Harper J, Damiani G, Shaw K, Obagi S, Salem RJ, Tanaka SK, Bunick CG. Grada A, et al. Front Med (Lausanne). 2022 Dec 8;9:1033980. doi: 10.3389/fmed.2022.1033980. eCollection 2022. Front Med (Lausanne). 2022. PMID: 36569144 Free PMC article.
• Tetracyclines and bone: Unclear actions with potentially lasting effects.
  Warner AJ, Hathaway-Schrader JD, Lubker R, Davies C, Novince CM. Warner AJ, et al. Bone. 2022 Jun;159:116377. doi: 10.1016/j.bone.2022.116377. Epub 2022 Mar 3. Bone. 2022. PMID: 35248788 Free PMC article. Review.
• Antioxidant for Neurological Diseases and Neurotrauma and Bioengineering Approaches.
  Rizwana N, Agarwal V, Nune M. Rizwana N, et al. Antioxidants (Basel). 2021 Dec 29;11(1):72. doi: 10.3390/antiox11010072. Antioxidants (Basel). 2021. PMID: 35052576 Free PMC article. Review.

References

1. 1. Infection. 1974;2(3):137-41 - PubMed
2. 1. J Pharmacol Exp Ther. 1963 May;140:258-66 - PubMed
3. 1. Curr Ther Res Clin Exp. 1973 Aug;15(8):578-80 - PubMed
4. 1. West J Med. 1974 Jun;120(6):452-5 - PubMed
5. 1. Jpn J Antibiot. 1969 Dec;22(6):483-7 - PubMed

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Ovid Technologies, Inc.
  • Springer